• / Free eNewsletters & Magazine
  • / My Account
Home>Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat.

Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat.

Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat.

09/28/2017

Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat.

  • Results demonstrate a very strong synergistic effect between AsiDNA™, first-in-class DNA break repair inhibitor (DBRi), and histone deacetylase inhibitors (HDACi)
  • This synergy is particularly high for the combination of its two proprietary assets, AsiDNA™ and belinostat,
  • Potential application of AsiDNA™ in combination with any HDACi fully covered by a key worldwide patent application

Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a French biotechnology company specializing in the development of innovative drugs in oncology, in particular orphan cancers, today announced compelling results from extensive in-vitro preclinical studies of combinations of AsiDNA™ a first-in-class DNA break repair inhibitor (DBRi) with histone deacetylase inhibitor (HDACi), including belinostat, on various tumor cell lines. These data and potential future applications have been fully protected by a patent application filed today covering the use of AsiDNA™ in combination with any HDAC inhibitor in any treatment scheme.

Based on scientific evidence that HDAC inhibitors increase two-strand DNA breaks in tumor cells, the company has performed combination experiments demonstrating the synergistic effect of the association of AsiDNA™, its first-in-class DBRi, with HDAC inhibitors, including with its other key strategic asset belinostat, a multi-potent HDACi.

The study evaluated the efficacy of the combination on tumor cells lines and healthy cells compared to each compound alone. The results are expressed as percentage of living cells relative to non-treated condition.

The combination shows (pink bars) a very high level of efficacy (very limited detectable surviving cancer cells) compared to each compound alone, with statistical significance, on both the liquid and the solid tumor cell line. On the contrary, there was no effect on healthy cells lines, neither from compounds alone or the combination which is encouraging in terms of safety profile of the combination

Notable highlights from these in-vitro preclinical studies are:

©2017 Morningstar Advisor. All right reserved.